NewcelX (NCEL)
Develops stem-cell-derived islet and astrocyte therapies for diabetes and ALS.
Something off on this page? Send us feedback.
Develops off-the-shelf stem-cell-derived pancreatic islets for type 1 diabetes and astrocyte therapies for ALS, while retaining an early-stage CNS small-molecule platform. Has no approved products and depends on partners for clinical manufacturing, immune modulation, and foundational technology licenses.
Develops stem-cell-derived pancreatic islets for type 1 diabetes and astrocyte therapies for ALS, with DOXA extending the portfolio into early-stage CNS small molecules. Its lead NCEL-101, also called IsletRx, uses enriched insulin-secreting cells made from a human embryonic stem-cell line and is in IND-enabling development; AstroRx has completed an Israeli early-stage study and is planned for a U.S. study.
Operates from Switzerland and Israel, with research and laboratories concentrated in Israel. Development depends on outsourced clinical manufacturing by Pluri, an investigational immunosuppressive component supplied through the Eledon collaboration, and licensed Yeda intellectual property. No products are approved, and future revenue depends on clinical success, regulatory approval, commercialization, or partnering and licensing arrangements.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Dec 31, 2025Cash & short-term investments $2.2M · Total debt $355.0K · Total assets $11.4M · Shareholders' equity $7.3M
- Revenue
- $0
- Operating income
- −$4.1M
- Net income
- $4.3M
No dividends on record.
| Institutions4 holders · as of Jun 30, 2026 | ≥ 2.65% | 11.9K ADS | |
| Insiders3 holders · as of Apr 29, 2026 | 24.29% | 109.3K ADS | |
| Otherremainder | ≤ 73.06% | 328.8K ADS |
450.0K ADS (1 ADS = 12 ordinary shares) as of Aug 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count is from the company's Dec 2023 annual report; nothing newer is on file here.
Institutional filings for NLSPW (1,200% of the company) are not on file here, so the institutional figure is a floor.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Michel RevelInsiderdirector, 10 percent owner, officer: CSO and Director | 17.73% | 957,530 ordinary | Form 4filed Apr 29, 2026 ↗ |
Ronen TwitoInsiderdirector, officer: Chairman and CEO | 5.04% | 272,399 ordinary | Form 4filed Mar 18, 2026 ↗ |
HRT Financial LPInstitution | 2.49% | 11,199 ADS | 13Fas of Jun 30, 2026 |
Olivier SamuelInsiderdirector | 1.52% | 81,818 ordinary | Form 4filed Apr 29, 2026 ↗ |
Jones Financial Companies LLLPInstitution | 0.16% | 700 ADS | 13Fas of Jun 30, 2026 |
| See all 10 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 27, 2026 | Michel Revel | director, 10 percent owner, officer: CSO and Director | +130,908 | $2.91 |
| Apr 27, 2026 | Olivier Samuel | director | +196,363 | $2.91 |
- Vertex Pharmaceuticals
Stem-cell islet therapy leader in type 1 diabetes.
- Sana Biotechnology
Hypoimmune stem-cell islets target insulin independence.
- Century Therapeutics
Immune-evasive iPSC islets target a functional T1D cure.
- Biogen
QALSODY is a marketed therapy for SOD1-mutated ALS.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| NewcelX | $3.48 | +5.78% | $1.5M | 5.3 | — | — | — |
| Vertex Pharmaceuticals | $555.40 | −0.23% | $141.31B | 32.4 | 28.6 | 11.2 | +12.5% |
| Sana Biotechnology | $3.95 | +1.28% | $1.08B | — | — | — | — |
| Century Therapeutics | $1.91 | −9.91% | $182.7M | — | — | — | — |
| Biogen | $222.65 | −0.03% | $32.90B | 39.4 | 16.8 | 3.3 | +3.4% |
| Median | 35.9 | 22.7 | 7.3 | +7.9% |